期刊文献+

CA125血清水平对上皮性卵巢肿瘤的诊断价值 被引量:1

原文传递
导出
摘要 目的:探讨CA125作为上皮性卵巢癌诊断标志物的临床价值。方法:随机选择健康女性50例、良性卵巢肿瘤患者50例、上皮性卵巢癌患者52例作为研究对象,检测各组人群血清CA125蛋白表达水平。结果:3组研究对象的年龄没有统计学差异(F=22.14,P=0.134);上皮性卵巢癌患者的血清CA125水平明显高于健康女性与良性卵巢肿瘤患者(P值均<0.01),卵巢良性疾病组CA125与正常对照组比较无统计学差异(P=0.562);CA125在卵巢癌晚期(Ⅲ期+Ⅳ期)高于卵巢癌早期(Ⅰ期+Ⅱ期),随着病情进展,呈上升趋势;非粘液性卵巢癌患者血清CA125明显升高,粘液性卵巢癌患者血清CA125升高不明显,2者血清CA125水平比较具有统计学差异(P<0.01);某些良性卵巢肿瘤CA125水平也会高于正常,但一般强度不高。结论:作为上皮性卵巢癌肿瘤标记物,CA125有较好的诊断价值。
作者 卢晓平
出处 《中国伤残医学》 2012年第12期49-50,共2页 Chinese Journal of Trauma and Disability Medicine
  • 相关文献

参考文献5

  • 1Whitehouse C,Solomon E.Current status of the molecular charac-terization of the ovarian cancer antigen CA125and implication for its use in clinical screening[J].Gynecol Oncol,2003,88(1Pt2):S152-S157.
  • 2A Jaffe AB,Hall A.Rho GTPases:biochemistry and biology[J].Annu Rev Cell Dev Biol,2005,21:247-69.
  • 3马文丽,郑文岭.分子肿瘤学[M].第一版.北京:人民军医出社,2002.299-304.
  • 4丰有吉,沈铿,主编.妇产科学[M].第2版.北京:人民卫生出版社,2010:334-338.
  • 5周克平,谭新洛.卵巢癌抗原CA125[J].国外医学(妇产科学分册),1989,16(5):260-263. 被引量:8

共引文献28

同被引文献24

  • 1谭云昌,吕文静.癌胚抗原与抗原125联合检测在卵巢癌中的诊断价值[J].实用医技杂志,2006,13(22):3960-3961. 被引量:2
  • 2张晓霞,孙晓琦,何津,李荷莲.应用基因芯片筛查差异表达基因在卵巢癌早期诊断研究中的作用[J].中国实用妇科与产科杂志,2007,23(3):207-209. 被引量:2
  • 3Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer European Group on Tumor Markers guidelines for clinical use[J] lnt J (;ynecol Cancer,2005,15(5) :679 691.
  • 4Zivanovic O, Sima CS, Iasonos A, et al. Exploratory analysis of se rum CA-125 response to surgery and the risk o relapse in patients with FIGO stage IIIC ovarian Cancer [J. Gynecol Oncol, 2009, 115(2):209 214.
  • 5Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigenidentification as a new muein, MUC16[J. J Biol Chem, 2001,276(29) :27371-27375.
  • 6Beastall GH,Cook B,Rustin GJ,et al. A review of the role of es tablished tumour markersJ. Ann Clin Biochem, 1991,28 (Pt 1 ) . 5 18.
  • 7Gipson IK,Blalock T, Tisdale A, et al. MUC16 is lost from the uterodome (pinopode) surface of the receptive human endome trium=in vitro evidence that MUC16 is a barrier to trophoblast adherence[-J. Biol Reprod, 2008,78(1) : 134-142.
  • 8Kaneko SJ ,Gerasimova T, Smith ST, et al. CA125 and UQCRFS1 FISH studies of ovarian carcinoma[J]. Gynecol Oncol, 2003,90 (1) 29 36.
  • 9Gubbels JA, Felder M, Horibata S, et al. MUC16 provides im- mune protection by inhibiting synapse formation between NK and ovarian tumor cells[J. Mol Cancer, 2010,9 : 11 12.
  • 10Belisle JA,Gubbels JA, Raphael CA, et al. Peritoneal natural kil- ler cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125)[J. Immunology,2007,122(3) .418 429.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部